The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some safety setbacks and years of generic competition, Takeda is calling it quits ...

Riyadh, The Kingdom of Saudi Arabia: Takeda, the global biopharmaceutical company, is pleased to announce a new strategic ...

Ascentage Pharma Group (AAPG) (AAPGV) (OTCPK:ASPHF), which is backed by Takeda (NYSE:TAK), has priced a $126M U.S. initial public offering. The China-based drug developer priced 7.33M shares at $17.25 ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.

Takeda-backed Ascentage Pharma Group (AAPG) (ASPHF), which is developing treatments for blood cancers, has set terms for a ...

Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year.

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an evolution of our economic model that starts with IRA, and will get worse and ...

More than 250 people — a mix of construction crew members, community and business leaders, and Takeda employees — braved ...

Atomi Financial Group Inc. trimmed its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) ...

LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage ...

Takeda Canada Inc. ("Takeda") announced that, for the third consecutive year, it has received Top Employer® certification for ...